Thursday, February 2, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

WHO and MPP announce the first transparent, global, non-exclusive license for a COVID-19 technology

in Innovation
Inflation transitory: goldman researcher
Share on FacebookShare on Twitter

WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) this Tuesday finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine.  This represents the first transparent, global, non-exclusive license for a COVID-19 health tool, and the first test license signed by MPP and included in the WHO Pool.

The aim of the license is to facilitate the rapid manufacture and commercialization of CSIC’s COVID-19 serological test worldwide. The agreement covers all related patents and the biological material necessary for manufacture of the test. CSIC will provide all know-how to MPP and/or to prospective licensees as well as training. The license will be royalty-free for low- and middle-income countries and will remain valid until the date the last patent expires.

“This license is a testament to what we can achieve when putting people at the center of our global and multilateral efforts,” said Carlos Alvarado Quesada, President of Costa Rica, the founding country of C-TAP. “It shows that solidarity and equitable access can be achieved and that it is worthwhile continuing to support the principles of transparency, inclusiveness and non-exclusivity that the C-TAP defends. Costa Rica welcomes the signing of this license and is convinced, today more than ever, that mechanisms such as C-TAP can help us overcome the current situation, while being beneficial for future health crises. I thank the Spanish Government and CSIC, for taking a step forward in solidarity and prioritizing health as a global public good.”

“This is the first technology developed by a public-funded institution that joins the C-TAP initiative,” said Diana Morant, Spanish Minister of Science and Innovation. “With agreements like this, we protect lives. Science has the universal purpose of improving people’s lives. Therefore this is also a firm commitment of our government: supporting a public system of science to serve all citizens.”

“I highly commend CSIC, a public research institute, for its commitment to solidarity and for offering worldwide access to their technology and know-how,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is the kind of open and transparent license we need to move the needle on access during and after the pandemic. I urge developers of COVID-19 vaccines, treatments and diagnostics to follow this example and turn the tide on the pandemic and on the devastating global inequity this pandemic has spotlighted.”

“Our strong partnership with WHO and C-TAP partners has been essential in negotiating this license, and I look forward to our continued collaboration, drawing on WHO’s expertise and guidance going forward,” said Charles Gore, Executive Director of MPP. “What is clear is that MPP’s model can work across different health technologies, and we are thrilled to be signing our first C-TAP/MPP test license with CSIC.”

Dr. Rosa Menéndez, president of CSIC, emphasized how important it is to seek solutions so that technologies related to the COVID-19 pandemic in particular, and health in general, reach all countries, including those most in need. “In this sense, we would like this action by CSIC, of taking part in the international initiatives of MPP and WHO, to become an example and a reference for other research organizations in the world.”

The technology to date has resulted in four different tests, one of which has the potential to distinguish the immune response of COVID-19 infected individuals from vaccinated individuals. This should aid further research into the level and length of immunity and the efficacy of the tools at our disposal.

The tests are simple to use and suitable for all settings with a basic laboratory infrastructure, such as those found in rural areas in low- and middle-income countries. The reading can theoretically be done manually (with naked eye comparing the color of the wells against the color chart), but an ELISA reader is recommended for greater accuracy of results.

Promising performance data in the European population will need to be supplemented by the companies that will produce this technology if they plan to sell the test in low- and middle-income countries.

Tags: COVID-19MPPnon-exclusive licenseTechnology

Related Posts

Business benefits of a customer self-service strategy
Business

Business benefits of a customer self-service strategy

When retail buyers panic, a. I. Keeps calm
Business

When Retail Buyers Panic, A.I. Keeps Calm

A simpler path to better computer vision
Business

A Simpler Path to Better Computer Vision

Trust, risk, and opportunity: overseeing a comprehensive data and privacy strategy
Innovation

Trust, Risk, and Opportunity: Overseeing a Comprehensive Data and Privacy Strategy

Engineers solve a mystery on the path to smaller, lighter batteries
Innovation

Engineers Solve a Mystery on the Path to Smaller, Lighter Batteries

Adopting an ecosystem-first mindset in software
Business

Adopting an Ecosystem-First Mindset in Software

Deep tech powers new net-zero business models
Business

Deep Tech Powers New Net-Zero Business Models

Mit engineers develop a low-cost terahertz camera
Business

MIT Engineers Develop a Low-Cost Terahertz Camera

Using machine learning to identify undiagnosable cancers
Innovation

Using Machine Learning to Identify Undiagnosable Cancers

Show me the digital value
Innovation

Show Me the Digital Value

No Result
View All Result

Recent Posts

  • Tinder owner to lay off 8% of its staff as growth falters
  • Biden moves to slash U.S. credit card fees, app charges
  • New York City Votes To “Skip The Stuff” In Take-Out Orders
  • How to Test If Your Interview Process Is a Nightmare
  • The Next Era of Work Will Be About Skills, Not Pedigree

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Editor-In-Chief – caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In